A list of 350 medicines with their maximum prices has been submitted to Parliament, revealing substantial price reductions for several drugs, including those used in cancer treatment.
Dr. Ananda Wijewickrama, Chairman of the National Medicines Regulatory Authority, stated that the reductions range from 40 percent to as much as 15,667 rupees for certain medicines.
Notable price cuts include:
-
Faclitaxel (cancer treatment) – reduced by 15,667 rupees
-
Adlimumab – reduced by 33,783 rupees
-
Cesatri Curium Besilate – reduced by 547 rupees
-
Losartan Potassium – reduced by 3 rupees
-
Mebendazole – reduced by 33 rupees
These adjustments are part of ongoing efforts to make essential medicines more affordable for patients.
